Q BioMed (QBIO) Issued Bullish Valuation Outlook on Liver Cancer Drug
(NEW YORK)–Ludlow Research issued research alert to its subscribers on Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, with $0.10+ price target based on current market cap valuation, and potential for its Liver cancer drug patent. On Feb. 10, […]
Continue Reading